Osta Therapeutics appoints executives for antibiotic resistance strategy

Osta Therapeutics has appointed Gilles Courtemanche as senior scientific advisor and Nicolas Guyon-Geccllin as chief business officer to support the company’s strategy to develop novel antibiotic molecules to stop the rise of antibiotic resistance. Osta’s lead candidate, OSTA27, targets carbapenem-resistant acinetobacter baumannii (CRAb) infections and is currently in preclinical development. Dr Courtemanche brings more than 20 years’ experience in drug development from positions at Rhône-Poulenc, Sanofi and Synthelabo. Most recently, he was associate director, antimicrobials unit head at Bioaster. He holds a PhD in chemistry from the Pierre and Marie Curie University, Paris, France. Dr Guyon-Gellin has more than 18 years’ experience in biotech business development and finance. Most recently, he was chief business officer at Calypso Biotech, which was acquired by Novartis in 2024. He holds an MD from Université Paris Descartes (Paris V) and an MBA from ESCP Business School, both France.

Osta announced the appointments on 30 January 2025.